Vontobel Holding Ltd. Sells 29,019 Shares of Qiagen (NYSE:QGEN)

Vontobel Holding Ltd. lessened its position in shares of Qiagen (NYSE:QGEN) by 54.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,186 shares of the company’s stock after selling 29,019 shares during the period. Vontobel Holding Ltd.’s holdings in Qiagen were worth $1,090,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in QGEN. Creative Planning grew its holdings in shares of Qiagen by 12.7% in the 3rd quarter. Creative Planning now owns 40,571 shares of the company’s stock valued at $1,849,000 after acquiring an additional 4,561 shares in the last quarter. CWM LLC raised its position in shares of Qiagen by 11.5% in the third quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after buying an additional 287 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Qiagen by 37.3% in the third quarter. Handelsbanken Fonder AB now owns 73,304 shares of the company’s stock valued at $3,340,000 after buying an additional 19,900 shares in the last quarter. Finally, Park Avenue Securities LLC acquired a new stake in shares of Qiagen in the third quarter valued at approximately $304,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of NYSE QGEN opened at $43.00 on Monday. The firm’s 50-day moving average price is $45.10 and its 200-day moving average price is $43.54. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.44. The firm has a market capitalization of $9.81 billion, a P/E ratio of 143.09, a P/E/G ratio of 3.36 and a beta of 0.39. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same quarter in the prior year, the business earned $0.53 earnings per share. The business’s quarterly revenue was down .2% compared to the same quarter last year. Equities research analysts anticipate that Qiagen will post 2.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on QGEN. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday. Robert W. Baird boosted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research note on Thursday, June 27th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.12.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.